The effects of fluostigmine, phospholine and compound 217 AO on abnormalities of muscle action potentials caused by complete inhibition of acetylcholinesterase.
D000200:Action Potentials / Q000187:drug effects*; D000818:Animals; D001919:Bradycardia / Q000209:etiology; D055598:Chemical Phenomena; D002621:Chemistry; D002800:Cholinesterase Inhibitors; D004123:Dimethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004456:Echothiophate Iodide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D007531:Isoflurophate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D009469:Neuromuscular Junction / Q000187:drug effects; D009946:Organothiophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D051381:Rats; D009435:Synaptic Transmission / Q000187:drug effects; D013997:Time Factors
D002800:Cholinesterase Inhibitors; D004123:Dimethylamines; D009946:Organothiophosphorus Compounds; D007531:Isoflurophate; D004456:Echothiophate Iodide